Vicarious Surgical completes controlled builds; on track for production-equivalent system by mid-2026

Vicarious Surgical Inc.

Controlled builds completed in April and August 2025 under full QMS, demonstrating reproducibility and scalability.
System functionality increased from 49% (June) to 63% (Sept 2025); on path to 100% by mid-2026.
Launch indication is ventral hernia repair; 66% of US ventral hernias are still performed open (Fry et al. 2024).
Targeting clinical readiness by year-end 2026 and human clinical trials in 2027 to support De Novo submission.
IP portfolio includes 160 patents (50 granted/allowed, 110 pending) covering core innovations.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.